Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection

BACKGROUND: Tisagenlecleucel, an anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy, has demonstrated durable efficacy and a manageable safety profile in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) in the ELIANA pivotal trial and re...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunother Cancer
Hlavní autoři: Hall, Erin M, Yin, Dwight E, Goyal, Rakesh K, Ahmed, Atif A, Mitchell, Grace S, St. Peter, Shawn D, Flatt, Terrie G, Ahmed, Ibrahim A, Li, Weijie, Hendrickson, Richard J, August, Keith J, Myers, G Doug
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2021
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7818837/
https://ncbi.nlm.nih.gov/pubmed/33472856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001225
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky